Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 6/20 | 0.53 |
| ▸ | MMP9 | P14780 | 6/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | GLS | O94925 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.51 |
| ▸ | MMP3 | P08254 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7342436 | 0.90 | MMP2 (0.52) | ALDH1A1CA12CA9MMP2MMP9 | |
| SCHEMBL7348786 | 0.86 | MMP2 (0.51) | ALDH1A1CA12CA9MMP2MMP9 | |
| SCHEMBL1781793 | 0.86 | ALDH1A1 (0.55) | ALDH1A1CA12CA9MMP2MMP9 | |
| SCHEMBL1286243 | 0.86 | ALDH1A1 (0.55) | ALDH1A1CA12CA9MMP2MMP9 | |
| SCHEMBL20556320 | 0.85 | MMP2 (0.51) | ALDH1A1MMP2MMP9SMN1; SMN2MAPT | |
| SCHEMBL6579299 | 0.84 | MMP2 (0.52) | ALDH1A1CA12CA9MMP2MMP9 | |
| SCHEMBL7286787 | 0.84 | CA12 (0.51) | ALDH1A1CA12CA9MMP2MMP9 | |
| SCHEMBL7286779 | 0.84 | CA12 (0.51) | ALDH1A1CA12CA9MMP2MMP9 | |
| SCHEMBL876560 | 0.84 | SMN1; SMN2 (0.53) | ALDH1A1CA12CA9MMP2MMP9 | |
| SCHEMBL6579291 | 0.84 | MMP2 (0.52) | ALDH1A1CA12CA9MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | OWEN DAVID ALAN (GB) | 2003-11-06 | — | — | US | disclosed |
| EP-0923529-B1 | SUBSTITUTE 4-ARYLBUTYRIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | BAYER AG (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6118001-A | ANTICANCER AGENT; ANTIARTHRITIC AGENT | DARWIN DISCOVERY, LTD. (GB) | 2000-09-12 | — | — | US | disclosed |
| EP-0923529-A1 | SUBSITUTE 4-ARYLBUTYRIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | Bayer Corporation (US) | 1999-06-23 | — | — | EP | disclosed |
| US-5863915-A | ENZYME INHIBITORS FOR BONES AND JOINTS | BAYER CORPORATION (US) | 1999-01-26 | — | — | US | disclosed |
| WO-1997043238-A9 | SUBSTITUTED OXOBUTYRIC ACIDS AS MATRIX METALLOPROTEASE INHIBITORS | — | 1998-03-05 | — | — | WO | disclosed |
| WO-1997043237-A1 | SUBSITUTE 4-ARYLBUTYRIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | BAYER CORPORATION (US) | 1997-11-20 | — | — | WO | disclosed |
| EP-0046712-B1 | FLUORINATED DIAMINOBUTANE DERIVATIVES | MERRELL TORAUDE ET COMPAGNIE (FR) | 1985-02-06 | — | — | EP | disclosed |
| US-4435425-A | INHIBITORS OF GAMMA-AMINOBUTYRIC ACID TRANSAMINASE | MERRELL TORAUDE ET COMPAGNIE (FR) | 1984-03-06 | — | — | US | disclosed |
| EP-0046712-A1 | Fluorinated diaminobutane derivatives | MERRELL TORAUDE ET COMPAGNIE (FR) | 1982-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | MMP13, MMP2, MMP9 | ALDH1A1 408/4885CA12 134/4885CA9 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.